88 related articles for article (PubMed ID: 9713482)
1. Detection of p105 (c-erbB-2, HER2/neu) serum levels by a new ELISA in patients with ovarian carcinoma.
Marx D; Fattahi-Meibodi A; Kudelka R; Uebel T; Kuhn W; Meden H
Anticancer Res; 1998; 18(4B):2891-4. PubMed ID: 9713482
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of p105 (c-erbB-2 HER2/neu) serum levels in patients with ovarian cancer.
Meden H; Marx D; Schauer A; Wuttke W; Kuhn W
Anticancer Res; 1997; 17(1B):757-60. PubMed ID: 9066616
[TBL] [Abstract][Full Text] [Related]
3. Elevated serum levels of a c-erbB-2 oncogene product in oral squamous cell carcinoma patients.
Chen CH; Lin YS; Lin CC; Yang YH; Ho YP; Tsai CC
J Oral Pathol Med; 2004 Nov; 33(10):589-94. PubMed ID: 15482324
[TBL] [Abstract][Full Text] [Related]
4. Effects of interfering and influencing factors on the analyses of p105 (c-erbB-2/HER-2) oncoprotein fragment in serum.
Mielke S; Meden H; Raab T; Wuttke W; Kuhn W
Anticancer Res; 1997; 17(4B):3125-7. PubMed ID: 9329617
[TBL] [Abstract][Full Text] [Related]
5. Serum levels of the c-erbB-2 (HER2/neu) encoded oncoprotein fragment p105 in normal pregnancies.
Meden H; Mielke S; Schauer A; Kuhn W
In Vivo; 1997; 11(1):51-4. PubMed ID: 9067773
[TBL] [Abstract][Full Text] [Related]
6. Study of pretreatment serum levels of HER-2/neu oncoprotein as a prognostic and predictive factor in patients with advanced nonsmall cell lung carcinoma.
Ardizzoni A; Cafferata MA; Paganuzzi M; Filiberti R; Marroni P; Neri M; Fontana V; Nicoló G; Perdelli L; Stampino CG; Rosso R; Puntoni R
Cancer; 2001 Oct; 92(7):1896-904. PubMed ID: 11745263
[TBL] [Abstract][Full Text] [Related]
7. Antibody immunity to the p53 oncogenic protein is a prognostic indicator in ovarian cancer.
Goodell V; Salazar LG; Urban N; Drescher CW; Gray H; Swensen RE; McIntosh MW; Disis ML
J Clin Oncol; 2006 Feb; 24(5):762-8. PubMed ID: 16391298
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of a manual ELISA kit for determination of HER2/neu in serum of breast cancer patients.
Gauchez AS; Ravanel N; Villemain D; Brand FX; Pasquier D; Payan R; Mousseau M
Anticancer Res; 2008; 28(5B):3067-73. PubMed ID: 19031958
[TBL] [Abstract][Full Text] [Related]
9. The presence of soluble c-erbB-2 in saliva and serum among women with breast carcinoma: a preliminary study.
Streckfus C; Bigler L; Dellinger T; Dai X; Kingman A; Thigpen JT
Clin Cancer Res; 2000 Jun; 6(6):2363-70. PubMed ID: 10873088
[TBL] [Abstract][Full Text] [Related]
10. ELISA for quantitation of serum C-erbB-2 oncoprotein in breast cancer patients.
Meenakshi A; Kumar RS; Kumar NS
J Immunoassay Immunochem; 2002; 23(3):293-305. PubMed ID: 12227416
[TBL] [Abstract][Full Text] [Related]
11. Detection of serum autoantibodies to tumor suppressor gene p53 with a new enzyme-linked immunosorbent assay in patients with ovarian cancer.
Marx D; Frey M; Zentgraf H; Adelssen G; Schauer A; Kuhn W; Meden H
Cancer Detect Prev; 2001; 25(2):117-22. PubMed ID: 11341346
[TBL] [Abstract][Full Text] [Related]
12. Tumor histology and stage but not p53, Her2-neu or cathepsin-D expression are independent prognostic factors in breast cancer patients.
Korkolis DP; Tsoli E; Fouskakis D; Yiotis J; Koullias GJ; Giannopoulos D; Papalambros E; Nikiteas NI; Spiliopoulou CA; Patsouris E; Asimacopoulos P; Gorgoulis VG
Anticancer Res; 2004; 24(3b):2061-8. PubMed ID: 15274401
[TBL] [Abstract][Full Text] [Related]
13. Neu oncogene expression in ovarian tumors: a quantitative study.
Huettner PC; Carney WP; Naber SP; DeLellis RA; Membrino W; Wolfe HJ
Mod Pathol; 1992 May; 5(3):250-6. PubMed ID: 1353878
[TBL] [Abstract][Full Text] [Related]
14. Serum sErbB1 and epidermal growth factor levels as tumor biomarkers in women with stage III or IV epithelial ovarian cancer.
Baron AT; Lafky JM; Boardman CH; Balasubramaniam S; Suman VJ; Podratz KC; Maihle NJ
Cancer Epidemiol Biomarkers Prev; 1999 Feb; 8(2):129-37. PubMed ID: 10067810
[TBL] [Abstract][Full Text] [Related]
15. [C-erbB-2 protein in ovarian epithelial cancer: correlation between expression in tumor tissue and blood levels].
Felip E; Encabo G; Vidal MT; Vera R; del Campo JM; Rubio D
Med Clin (Barc); 1995 Jun; 105(1):5-8. PubMed ID: 7637419
[TBL] [Abstract][Full Text] [Related]
16. Prognostic and predictive impact of the HER-2/ neu extracellular domain (ECD) in the serum of patients treated with chemotherapy for metastatic breast cancer.
Müller V; Witzel I; Lück HJ; Köhler G; von Minckwitz G; Möbus V; Sattler D; Wilczak W; Löning T; Jänicke F; Pantel K; Thomssen C
Breast Cancer Res Treat; 2004 Jul; 86(1):9-18. PubMed ID: 15218357
[TBL] [Abstract][Full Text] [Related]
17. Comparison of serum HER2/neu with immunohistochemical HER2/neu expression for the prediction of biochemical progression in metastatic prostate cancer.
Tambo M; Higashihara E; Terado Y; Nutahara K; Okegawa T
Int J Urol; 2009 Apr; 16(4):369-74. PubMed ID: 19207111
[TBL] [Abstract][Full Text] [Related]
18. [Serum her-2/neu level and related factors in patients with breast cancer].
Yuan P; Xu BH; Zhang C; Qi J
Zhonghua Zhong Liu Za Zhi; 2003 Nov; 25(6):573-4. PubMed ID: 14690565
[TBL] [Abstract][Full Text] [Related]
19. Serum levels of HER2 ECD can determine the response rate to low dose oral cyclophosphamide and methotrexate in patients with advanced stage breast carcinoma.
Sandri MT; Johansson H; Colleoni M; Zorzino L; Passerini R; Orlando L; Viale G
Anticancer Res; 2004; 24(2C):1261-6. PubMed ID: 15154657
[TBL] [Abstract][Full Text] [Related]
20. The correlation of c-erbB-2 oncoprotein and established prognostic factors in human breast cancer.
Sütterlin MW; Haller A; Gassel AM; Peters K; Caffier H; Dietl J
Anticancer Res; 2000; 20(6D):5083-8. PubMed ID: 11326673
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
